Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar

Valspodar, a P-glycoprotein modulator, affects pharmacokinetics of doxorubicin when administered in combination, resulting in doxorubicin dose reduction. In animal models, valspodar has minimal interaction with pegylated liposomal doxorubicin (PEG-LD). To determine any pharmacokinetic interaction in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Fracasso, P M, Blum, K A, Ma, M K, Tan, B R, Wright, L P, Goodner, S A, Fears, C L, Hou, W, Arquette, M A, Picus, J, Denes, A, Mortimer, J E, Ratner, L, Ivy, S P, McLeod, H L
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361488/
https://ncbi.nlm.nih.gov/pubmed/15942626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602653
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares